Varaha S. Tammisetti, MD

Education

Medical School

Andhra Medical College, Visakhapatnam, India, 1997

Residency

Pediatrics/Radiology, Andhra Medical College, Visakhapatnam, India, 2000

Residency

Radiodiagnosis, Nizam’s Institute of Medical Sciences, Hyderabad, India, 2003

Fellowship

Radiology, Harborview Medical Center - University of Washington, Seattle, WA, 2006

Fellowship

Nuclear Medicine, University of Washington, Seattle, WA, 2007

Fellowship

Abdominal Imaging, University of Washington, Seattle, WA, 2008

Areas of Interest

Research Interests

**Faculty profiles will only highlight current information (the last three years). Please request the faculty’s CV for more information.

Active Research

1. FUNDED study – IRB No: HSC-MS-16-0316; Co-investigator “A study of MR/US fusion imaging and biopsy in combination with Nanoparticle directed Focal therapy for ablation of prostate tissue – MRI/US fusion guided AuroLase therapy” https://clinicaltrials.gov/ct2/show/NCT02680535?term=aurolase&draw=2&rank=4
2. FUNDED study – An Extension Study MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue https://clinicaltrials.gov/ct2/show/NCT04240639?term=aurolase&draw=2&rank=3
3. FUNDED study: Co-investigator on IRB-approved study with the UT School of Bioinformatics on Machine learning in the detection of Endometriosis on MR
4. IRB No: HSC-MS-17-0713; Co-investigator “A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) /
   Protocol No. MK-3475-564”
5. IRB No: HSC-MS-19-0300; Co-investigator Protocol RAD1901-308 – Elacestrant Monotherapy vs Standard of Care for the Treatment of Patients with ER+/HER2-Advanced Breast Cancer Following CDK4/6 inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active Controlled, Multicenter Trial (EMERALD)
6. Feasibility clinical study: Ferumoxytol (USPIO Nanoparticle) enhanced blood pool MRA as a last resort modality to identify the source of small bowel GI bleeding
7. IRB No: HSC-MS-20-0049; Site Co-Investigator “Phase 2, Multicenter, Double-blind (sponsor-unblinded) Randomized, placebo-controlled study of the safety and efficacy of Elagolix in women with polycystic ovary syndrome”
8. IRB No: HSC-MS-19-0886; Site Co-Investigator “A phase 3 study to evaluate the efficacy of Elagolix for the management of Heavy menstrual bleeding associated with fibroids in premenopausal women”
9. IRB No: HSC-MS-20-0001; Site Co-Investigator “A phase 2 multicenter, Randomized, double-blind placebo-controlled, clinical study to assess the safety and efficacy of linzagolix in subjects with moderate to severe endometriosis-associated pain”
10. IRB No: HSC-MS-20-0261; Site Co-Investigator “A phase 3b study to evaluate the safety and efficacy of Elagolix in combination with combined oral contraceptives in premenopausal women with documented endometriosis and associated moderate to severe pain”
11. IRB No: HSC-MS-21-0066; Co-investigator “Endoscopic Ultrasound Pancreatic Cancer Radiofrequency Ablation: A Phase II PANCARDINAL-1 Trial”
12. IRB No: HSC-MS-21-0372; Co-investigator “PD-Inhibitor(Nivolumab) and Ipilimumab Followed By Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE) Protocol # A031704”
13. IRB No: HSC-MS-13-0581; Outcomes observed in Neoadjuvant Prostate Cancer treatment

Publications